Studies of mTOR inhibitors in people
52 studies gave mTOR inhibitors to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases investigator's Global Assessment success72.4% versus 33.3%; adjusted relative risk 1.949 (95% CI 1.153–3.294) down: Decreases approximate protrusion volume−61.556 units; P < .001 | Randomized trial12 weeks | 65 peopleHyperplastic rosacea | Journal of the American Academy of Dermatology, Nov 10, 2026 |
up: Increases total cholesterolWeek 18 total cholesterol: 236.0 versus 219.6 mg/dl; LDL cholesterol: 151.7 versus 136.8 mg/dl; triglycerides: 159.4 versus 133.2 mg/dl up: Increases C-reactive protein down: Decreases hemoglobin-related parameters | Randomized trial18 weeks | 63 peopleALS | Frontiers in pharmacology, Oct 30, 2026 |
up: Improves clinical response3 months: 4/5 (80%; 95% CI 28–99); 12 months: 3/4 evaluable (75%; 95% CI 19–99) | Treated cohort3 and 12 months | 5 peopleAdd-on treatment for active refractory iMCD-TAFRO | Frontiers in immunology, Oct 16, 2026 |
up: Increases cerebral blood flow no change: Has no effect on cerebral blood flow | Trial4-week | 23 peopleaged 45 to 65 yearsCognitively normal adults aged 45 to 65 years | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Sep 10, 2026 |
up: Improves exercise-induced insulin sensitivity53% on average versus placebo | Randomized trial | Men | bioRxiv, Sep 2, 2026 |
up: Improves FEV1 up: Improves health-related quality of life | Trial24 weeks | 48 peopleWomen42(37-49) year oldSirolimus-naive LAM patients | American Journal of Respiratory and Critical Care Medicine, May 1, 2026 |
no change: Has no effect on 30-s chair stand test−2.13 repetitions, 95% CI −4.61 to 0.34 down: Impairs 30-s chair stand test−3.44 repetitions, 95% CI −5.86 to −0.99 no change: Has no effect on 6-minute walk distance−4.87 m, 95% CI −28.97 to 19.71 | Randomized trial13 weeks | 40 peopleBoth65–85 yearsCommunity‐dwelling adults aged 65–85 years | Journal of cachexia, sarcopenia and muscle, Apr 1, 2026 |
down: Decreases major adverse limb eventsrisk difference -4.9 percentage points (95% CI -8.5 to -1.3); 8.8% vs 15.0% no change: Has no effect on mortalityrisk difference -1.0 percentage points (95% CI -4.6 to 2.7); P = 0.67 | Randomized trial1 year | 1,252 peopleBothmedian 75 yearsOlder adults; primary composite of unplanned major amputation or target-lesion revascularization for critical limb ischemia within 1 year | The New England journal of medicine, Mar 30, 2026 |
up: Increases late diastolic (A-wave) kinetic energy up: Increases left retinal ganglion cell layer thickness | Trial26 weeks | 14 peopleEarly-stage Alzheimer's disease; uncontrolled pre-post comparison | medRxiv, Mar 12, 2026 |
no change: Has no effect on primary vessel patency73.9% versus 74.9%; risk difference -1.0 percentage points (95% CI -9.6 to 7.6); noninferiority not statistically robust no change: Has no effect on freedom from clinically driven target vessel revascularization, major target limb amputation, and device- or procedure-related death90.5% versus 92.7%; risk difference -2.2 percentage points (95% CI -7.7 to 3.2); Pnoninferiority = 0.003 | Randomized trial12 months | 482 peopleBoth68.0 ± 8.9 yearsOlder adults; symptomatic femoropopliteal artery disease | Journal of the American College of Cardiology, Feb 18, 2026 |
up: Improves progression-free survival11.8 months vs 1.8 months no change: Has no effect on overall survival38.3 vs 38.2 months | Randomized trial | 30 peopleMetastatic GEP-NEN or LCNEC after first-line chemotherapy | The oncologist, Jan 23, 2026 |
down: Decreases DNA lesional burden up: Increases cell survival3‐fold greater cell survival with over 60% cells still viable 24 h after zeocin treatment | Trial4 months | maleOlder male volunteers | Aging cell, Jan 12, 2026 |
down: Decreases plasma cytokines up: Increases cerebral blood flow up: Increases plasma cytokines | Trial4-12 weeks | 9 peopleBothmiddle-agedMidlife adults; Older adults; in APOE4 carriers in the prevention trial | GSA 2025 abstract, Dec 31, 2025 |
no change: Has no effect on cerebral glucose metabolism up: Increases cerebral glucose metabolism up: Increases CSF total tau, neurofilament light and amyloid-β 40 | Trial26 weeks | 14 peopleEarly-stage Alzheimer's disease, primary AD-signature regions | medRxiv, Dec 9, 2025 |
up: Improves pregnancy50.0% vs. 28.2%, RR 1.77, 95% CI 0.98 to 3.19 up: Increases blastocyst qualitymedian 1.0 vs. 0 | Trial21–28 days | 100 peoplewomenapproximately 36 yearsInfertile women who had a history of more than one IVF cycle failure | Cell reports. Medicine, Oct 27, 2025 |
up: Improves endothelial function up: Increases grip strength | Trial8 weeks | 6 people6 male subjects74.7 ± 2.4 yr.Male subjects (ages 70–76) who were in good overall health and devoid of any active cardiovascular problems | GeroScience, Sep 19, 2025 |
no change: Has no effect on rapamycin level no change: Has no effect on cognitive function up: Increases systolic blood pressure127.8 ± 19.0 vs 138.2 ± 22.1 mmHg | Trialeight-week | 10 people60% femalemean age 74 ± 4 yearsOlder adults with a clinical diagnosis of MCI or mild dementia due to AD | Communications medicine, May 20, 2025 |
no change: Has no effect on visceral adiposity up: Improves lean tissue massOR = 28, 95% CI = 2.42–323.7 down: Decreases painmd = 8.071 (95% CI = 3.044–13.098) | Randomized trial48 weeks | 114 people35.1% of participants overall (n = 40)aged 50–85 yearsHealthy individuals aged 50–85 years | Aging, Apr 4, 2025 |
up: Improves cerebral blood flow>15% up: Increases short-chain fatty acids no change: Has no effect on Tau | Trial4 weeks | 23 people45–65 yearsCognitively normal adults without diabetes | Research square, Mar 19, 2025 |
no change: Has no effect on adverse events no change: Has no effect on visceral adiposityη p2=0.001, p=0.942 up: Increases lean tissue massε2=0.202, p=0.013 | Randomized trial48 weeks | WomenWomen using 10 mg weekly | medRxiv, Aug 22, 2024 |
no change: Has no effect on oocyte maturation rate46.5–60.0% maturation across five groups; P = 0.30 no change: Has no effect on euploidy rate37.8–47.8% euploidy across five groups; P = 0.87 | Randomized trial24 h | 201 peopleWomen>38 yearsMidlife adults; rescue IVM of GV oocytes from women >38 years | Molecular human reproduction, Jan 5, 2024 |
down: Decreases mammary stem cell activity down: Decreases luminal progenitor self-renewal capacity down: Decreases luminal cell population | Trial5–7 days | 27 peoplewomenWomen of at least 18 years of age with confirmed menopausal status diagnosed with DCIS, LCIS, ADH, or ALH lesions scheduled for mastectomy or lumpectomy | Breast cancer research : BCR, Oct 30, 2023 |
| Treated cohort | 4 peopleChinese APDS2 patients from 4 unrelated families | Research Square, Apr 19, 2023 | |
up: Increases memory CD4+ and CD8+ T cells up: Increases effector memory CD4+ T cells down: Decreases MCP-1 | Trial6 months | Transfusion-dependent β-thalassemia patients | Journal of cellular and molecular medicine, Jan 10, 2023 |
no change: Has no effect on central subfield thickness-53.9 μm, p = 0.28 no change: Has no effect on visual acuity2.5 vs 0.8 letters, p = 0.42 | Randomized trial36 weeks | 20 peoplePatients with persistent, exudative AMD | International journal of retina and vitreous, Jan 5, 2023 |
up: Increases seroconversion56% vs 13% up: Increases SARS-CoV-2 IgG antibodies160 AU/mL (0–142) vs 0 AU/mL (0–0) no change: Has no effect on cellular response44% vs 50% | Randomized trial28 d | 32 people12 (38%) were female72 ± 4 yElderly (≥65 y), de novo KTRs | Transplantation, May 11, 2022 |
| Treated cohort | 1 personIn a GIMAP5-deficient patient | bioRxiv (Cold Spring Harbor Laboratory), Feb 23, 2021 | |
down: Decreases central subfield thickness-40 μm in sirolimus group vs +20 μm in anti-VEGF group no change: Has no effect on visual acuity | Randomized trialsix months | 20 peoplePatient cohorts | International journal of retina and vitreous, Feb 16, 2021 |
down: Decreases p16INK4a up: Increases collagen VII up: Improves skin appearance | Randomized trial8 months | 36 peoplegreater than 40 years of ageAdults greater than 40 years of age with no history of diabetes or hypercholesterolemia | GeroScience, Nov 25, 2019 |
down: Decreases clinical symptomssubstantial improvement (not quantified in abstract) | Treated cohort | 4 peopleFour rapamycin-treated patients with APDS1 | Journal of clinical immunology, Nov 29, 2018 |
down: Lowers the risk of infectionP = 0.001 up: Increases antiviral gene expression up: Improves influenza vaccination response | Randomized trial6 weeks | 264 peopleelderlyOlder adults; elderly subjects, low-dose combination given for 6 weeks | Science translational medicine, Jul 11, 2018 |
no change: Has no effect on geographic atrophy growth ratemean growth 4.94 vs 5.72 mm2 at month 24 (sirolimus vs sham); P=0.33 no change: Has no effect on best-corrected visual acuity change up: Increases sterile endophthalmitis3 participants in the sirolimus group | Randomized trial24 months | 52 peoplemean age 79 yearsOlder adults; monthly intravitreal injection in geographic atrophy versus sham | Ophthalmology. Retina, May 1, 2018 |
down: Decreases hemoglobin up: Increases regulatory T cells no change: Has no effect on cognitive function | Randomized trial8 weeks | 28 people70-95 years; mean age 80.5Healthy older persons | Experimental gerontology, Feb 3, 2018 |
no change: Has no effect on everolimus pharmacokinetic parameters across timepointsCtrough 4.7 ± 2.5 ng/mL; AUC0-12h 106 ± 51 ng/h per mL | Trialfirst 6 months after transplantation | 16 peopleBothmean 64 yearsOlder adults; with steady-state tacrolimus | Transplantation, Sep 1, 2017 |
down: Decreases seizure frequencymedian reduction 39.6% high exposure and 29.3% low exposure vs 14.9% placebo up: Increases seizure response rate40.0% vs 15.1% with placebo up: Increases grade 3 or 4 adverse events24% high exposure, 18% low exposure, 11% placebo | Randomized trial12-week maintenance period | 366 people2-65 yearsAdjunctive therapy in tuberous sclerosis complex with treatment-resistant focal-onset seizures | Lancet (London, England), Sep 6, 2016 |
down: Decreases DNA damage | Trialone year | 17 peopleSwitch from calcineurin inhibitors, one year after switch | European journal of cell biology, Jun 15, 2016 |
down: Decreases senescence-associated beta-galactosidase2.2% vs 3.6%; p=0.18 no change: Has no effect on frailty | Trial12 weeks | 13 peopleBothMedian age 73.9±7.5 yearsOlder adults; older adults with coronary artery disease undergoing cardiac rehabilitation | The Journal of frailty & aging, Jan 1, 2016 |
down: Lowers the risk of disease progression or deathHR 0.48, 95% CI 0.35–0.67 up: Improves progression-free survival11.0 vs 3.9 months down: Lowers the risk of mortalityHR 0.64, 95% CI 0.40–1.05 | Randomized trial | 302 peopleadults aged ≥18 yearsPatients with advanced, nonfunctional NET of lung or GI origin | Lancet (London, England), Dec 17, 2015 |
no change: Has no effect on progression-free survivalHR 0.89, 95% CI 0.73-1.08; median 14.95 vs 14.49 months up: Increases progression-free survivalmedian 20.27 vs 13.08 months (+7.2 months); HR 0.66 up: Increases stomatitis67% vs 32% of patients | Randomized trialmedian follow-up 41·3 months (IQR 35·4-46·6) | 719 people18 years or olderFull study population | The Lancet. Oncology, Jun 16, 2015 |
up: Improves response to influenza vaccinationabout 20% enhancement down: Decreases PD-1 expression on T lymphocytes | Randomized trial | elderlyOlder adults; in elderly volunteers | Science translational medicine, Dec 24, 2014 |